3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Melanoma
12
Colorectal Neoplasms
9
Lung Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Pancreatic Neoplasms
3
Colonic Neoplasms
3
Skin Neoplasms
2
Skin Diseases
2
Rectal Neoplasms
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Spinocerebellar Degenerations
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumor
1
Soft Tissue Neoplasms
1
Recurrence
1
Peripheral Nervous System Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Noonan Syndrome 5
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Interventions
Cyclophosphamide
67
Dexamethasone
52
Peripheral Blood Stem Cell Transplantation
37
Lenalidomide
37
Rituximab
35
fludarabine phosphate
34
Bortezomib
30
Filgrastim
27
Etoposide
27
Cytarabine
25
Carboplatin
25
Busulfan
23
Radiotherapy
22
Melphalan
22
Gemcitabine
22
Cyclosporine
21
pomalidomide
20
fludarabine
20
Whole-Body Irradiation
20
Mycophenolic Acid
20
Paclitaxel
19
Methotrexate
18
venetoclax
17
Cisplatin
17
pembrolizumab
16
Calcium Dobesilate
16
Bevacizumab
16
Tacrolimus
14
Antilymphocyte Serum
14
Nivolumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Recurrence
×
binimetinib
×
Clear all
NCT02834364
2023-11-24
GMMG-BIRMA
University of Heidelberg Medical Center
Phase 2
Completed
12 enrolled